Smith Sean Michael 4
4 · Neoleukin Therapeutics, Inc. · Filed Mar 3, 2022
Insider Transaction Report
Form 4
Smith Sean Michael
Principal Accounting Officer
Transactions
- Award
Stock Option (Right to Buy)
2022-03-02+80,000→ 80,000 totalExercise: $2.72Exp: 2032-03-01→ Common Stock (80,000 underlying)
Footnotes (1)
- [F1]1/4 of the shares subject to the option will vest on March 2, 2023, and 1/48 of the shares subject to the option will vest monthly thereafter, subject to the Reporting Person's provision of service to the Issuer on each vesting date.